5:34 PM
 | 
Oct 03, 2013
 |  BC Extra  |  Company News

Orexigen submits Contrave MAA

Orexigen Therapeutics Inc. (NASDAQ:OREX) submitted an MAA to EMA for Contrave naltrexone/bupropion to treat obesity. The company also reiterated plans to resubmit an NDA to FDA for...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >